Nicox announced that Tomas Navratil, PhD, Executive Vice President & Head of Research & Development of the Nicox Group and General Manager of Nicox Ophthalmics, will be leaving the company on October 16, 2020 to pursue other opportunities. Nicox has initiated a search for a successor. In the interim, Dr. José Boyer, the current Vice President and Head, Clinical Development, will be appointed as Interim Head of R&D, effective October 16, 2020.
“We are very appreciative of Dr. Navratil’s contributions to Nicox and the excellent R&D progress achieved across all programs in Nicox’s pipeline during his tenure and we wish him great success in his future endeavours,” Michele Garufi, Chairman and Chief Executive Officer of Nicox, said in a company news release. “I am confident that under Dr. Boyer’s leadership the R&D team will continue to successfully deliver on key milestones in the NCX 470 trials and the forthcoming NCX 4251 trial.”